Analysts take a look at Neurocrine Biosciences, Inc. (NASDAQ:NBIX) having this to say.

April 17, 2018 - By Winifred Garcia

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment decreased to 1.31 in Q4 2017. Its down 0.35, from 1.66 in 2017Q3. It worsened, as 18 investors sold Neurocrine Biosciences, Inc. shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported.
State Of Alaska Department Of Revenue holds 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 6,400 shares. Moreover, Paloma Prtnrs Mngmt has 0.04% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Geode Cap Management Limited Liability Corp accumulated 762,835 shares. Shell Asset Management reported 16,806 shares. Frontier Cap Management Com Limited Liability Corporation owns 120,225 shares. Arrowgrass Capital (Us) Ltd Partnership holds 0.06% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 74,300 shares. Bailard Inc accumulated 6,900 shares. Usa Fin Portformulas Corp has 0.12% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Loomis Sayles And Comm L P owns 114,779 shares. Balyasny Asset holds 0.09% or 362,049 shares in its portfolio. Fny Managed Accounts Limited Liability Company holds 0% or 43 shares in its portfolio. Grandfield And Dodd Ltd Liability Co holds 0.07% or 7,915 shares. Opus Point Prns Management Ltd accumulated 4,204 shares or 0.28% of the stock. 6.23M are held by Price T Rowe Md. Manufacturers Life Ins Com The holds 2,641 shares or 0% of its portfolio.

Since January 2, 2018, it had 0 buys, and 22 selling transactions for $29.59 million activity. Gano Kyle had sold 1,625 shares worth $128,460 on Tuesday, January 16. 820 shares valued at $68,174 were sold by BENEVICH ERIC on Monday, February 5. $138,499 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by OBrien Christopher Flint. 5,000 shares were sold by LYONS GARY A, worth $423,341. Another trade for 86,368 shares valued at $6.76 million was made by Grigoriadis Dimitri E. on Friday, February 9. $128,575 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Bozigian Haig P..

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 11 analysts covering Neurocrine (NASDAQ:NBIX), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine had 27 analyst reports since October 20, 2017 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Friday, March 16. As per Wednesday, November 1, the company rating was maintained by BMO Capital Markets. Oppenheimer maintained the stock with “Buy” rating in Monday, January 15 report. The rating was maintained by Robert W. Baird with “Buy” on Monday, October 23. Deutsche Bank maintained it with “Buy” rating and $79.0 target in Thursday, November 2 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Wednesday, March 21. Oppenheimer maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, November 14 with “Buy” rating. Needham maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, February 22. Needham has “Buy” rating and $110.0 target. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, March 13 by Oppenheimer. Oppenheimer maintained it with “Buy” rating and $85.0 target in Tuesday, December 12 report. Below is a list of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) latest ratings and price target changes.

21/03/2018 Broker: Oppenheimer Rating: Buy Maintain
16/03/2018 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
14/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $113.0 Maintain
13/03/2018 Broker: Oppenheimer Rating: Buy New Target: $110.0 Maintain
22/02/2018 Broker: Oppenheimer Rating: Buy New Target: $110.0 Maintain
22/02/2018 Broker: Needham Rating: Buy New Target: $110.0 Maintain
20/02/2018 Broker: Leerink Swann Rating: Buy New Target: $96.0 Maintain
14/02/2018 Broker: Deutsche Bank Rating: Buy New Target: $97.0 Maintain
14/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $139.0 Maintain
14/02/2018 Broker: Oppenheimer Rating: Buy New Target: $100.0 Maintain

The stock increased 2.62% or $1.97 during the last trading session, reaching $77.27. About 488,246 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since April 17, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $6.95 billion. The companyÂ’s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for womenÂ’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with ParkinsonÂ’s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.